GMOD yields 0.92% · JNJ yields 2.14%● Live data
📍 JNJ pulled ahead of the other in Year 6
Combined, GMOD + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GMOD + JNJ for your $10,000?
GMOD seeks positive total return through a dynamic, multi-asset allocation approach that adjusts exposures across equities, fixed income, and liquid alternative strategies based on GMOs long-term valuation and risk outlook. The fund typically operates as a fund of funds, investing mainly in other GMO-managed and third-party vehicles but may also hold securities directly. Allocation decisions are guided by GMOs forecasts of expected returns and its view that valuations tend to revert to fair value over time. This forward-looking process incorporates assessments of relative risk, economic trends, and market conditions to determine where capital is best positioned. The portfolios flexibility allows allocations to shift meaningfully, with equity exposure generally ranging between 40% and 80% of net assets. While diversified across asset classes, the fund can concentrate in certain markets or sectors when valuation signals support a higher conviction stance.
Full GMOD Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.